ZFIN ID: ZDB-FISH-150901-8500
Fish name: la116Tg
Genotype: la116Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by la116Tg
Human Disease Conditions Citations
cancer cancer xenotransplantation Wang et al., 2017
cancer xenotransplantation Gao et al., 2017
cancer xenotransplantation Schaefer et al., 2015
squamous cell carcinoma cancer xenotransplantation von Mässenhausen et al., 2016
GENE EXPRESSION
Gene expression in la116Tg
RNA expression
Expressed Gene Structure Conditions Figures
adgrg6 standard conditions Fig. 4 from Cui et al., 2014
adora2b standard conditions Fig. 2 from Jing et al., 2015
alcama standard conditions Fig. 2,  Fig. S7 from Lagendijk et al., 2011
Fig. 1 with image from Smith et al., 2011
chemical treatment: pharmaceutical Fig. 7 from Lagendijk et al., 2011
bmp2b standard conditions Fig. S3 with image from Mouillesseaux et al., 2011
bmp4 standard conditions Fig. S3 with image from Mouillesseaux et al., 2011
col1a2 standard conditions Fig 1 with image from Rajan et al., 2020
col5a1 standard conditions Fig 1 with image from Rajan et al., 2020
dld standard conditions Fig. 1 with image from Fujita et al., 2011
dre-mir-24-4 control Fig. 1 with image from Kasper et al., 2017
dre-mir-139 control Fig. 1 with image from Kasper et al., 2017
egr2b standard conditions Fig. S1 with image from Mouillesseaux et al., 2011
flt4 standard conditions Fig. 2 with image from Mouillesseaux et al., 2011
ftr82 standard conditions Fig. 2 with image from Chang et al., 2017
hey2 standard conditions Fig. 2 with image from Mouillesseaux et al., 2011
itgav control Fig. 2 with image from Liu et al., 2012
itgb8 control Fig. 2 with image from Liu et al., 2012
kdrl standard conditions Fig. 4 from Cui et al., 2014
mir24-1 control Fig. 1 with image from Kasper et al., 2017
mir24-2 control Fig. 1 with image from Kasper et al., 2017
mir24-3 control Fig. 1 with image from Kasper et al., 2017
mir223 control Fig. 1 with image from Kasper et al., 2017
myb standard conditions Fig. S1 with image from Mouillesseaux et al., 2011
myod1 standard conditions Fig. 4 from Cui et al., 2014
nlgn1 standard conditions Fig. S1 from Rissone et al., 2012
nrxn1a standard conditions Fig. S1 from Rissone et al., 2012
rbpja standard conditions Fig 6 with image,  Fig 8 with image from Serrano et al., 2019
chemical treatment by environment: DAPT Fig 8 with image from Serrano et al., 2019
slco1c1 standard conditions Fig. 1 from Admati et al., 2019
sytl2a standard conditions Fig. 7 from Francis et al., 2021
sytl2b standard conditions Fig. 7 from Francis et al., 2021
tbx20 standard conditions Fig. 6 with image from Mouillesseaux et al., 2011
thbs1b standard conditions Fig. 6 with image,  Fig. S4 with image from Mouillesseaux et al., 2011
tjp1a standard conditions Fig. S4 with image from Liu et al., 2012
tp53 standard conditions Fig. S4 with image from Mouillesseaux et al., 2011
utp15 standard conditions Fig. 5 with image from Mouillesseaux et al., 2011
vegfaa standard conditions Fig. S3 with image from Mouillesseaux et al., 2011
xgb standard conditions Fig. 2 from Corti et al., 2016
Reporter gene expression
Expressed Gene Structure Conditions Figures
EGFP standard conditions Fig. 10 with image from Gao et al., 2017
Fig. S5 with image from Shin et al., 2016
Fig. 1 with image from Nicoli et al., 2012
Fig. 1,  Fig. 3,  Fig. 4 from Nicoli et al., 2010
chemical treatment: pharmaceutical Fig. 10 with image from Gao et al., 2017
Fig. S5 with image from Shin et al., 2016
Fig. 1 from Nicoli et al., 2010
cancer xenotransplantation Fig. 5 from Wang et al., 2017
Fig. 5 with image from Zhang et al., 2017
GFP standard conditions 81 figures with image from 40 publications
chemical treatment by environment: BAY-826 18 figures with image from 15 publications
chemical treatment by injection: docetaxel anhydrous, cancer xenotransplantation Fig. 3 from Jacob et al., 2018
Fig. 6 with image from Kasper et al., 2017
Fig. 6 from Gao et al., 2015
Fig. 5 with image from Schaefer et al., 2015
Fig. 6,  Fig. 7 from Wu et al., 2013
PHENOTYPE
Phenotype in la116Tg
Phenotype Conditions Figures
angiogenesis decreased process quality, abnormal chemical treatment by environment: doxorubicin, chemical treatment by environment: methoxypoly(ethylene glycol), chemical treatment by environment: poly(caprolactone) polymer, chemical treatment by environment: Honokiol Fig. 10 with image from Gao et al., 2017
aortic arch morphology, abnormal chemical treatment by environment: DAPT Fig 7 with image,  Fig 9 with image from Serrano et al., 2019
aortic arch morphology, normal control Fig 9 with image from Serrano et al., 2019
aortic arch cell population proliferation decreased occurrence, abnormal chemical treatment by environment: DAPT Fig 7 with image from Serrano et al., 2019
aortic arch 5 absent, abnormal chemical treatment: pharmaceutical Fig. 1 from Nicoli et al., 2010
aortic arch 5 absent, abnormal chemical treatment: pharmaceutical Fig. 1 from Nicoli et al., 2010
aortic arch 5 absent, abnormal chemical treatment: semaxanib Fig. 1 from Nicoli et al., 2010
atrioventricular valve malformed, abnormal chemical treatment by environment: ethanol Fig. 3 with image,  Fig. 4 with image from Sarmah et al., 2016
atrioventricular valve morphology, abnormal chemical treatment by environment: ethanol Fig. 3 with image,  Fig. 4 with image from Sarmah et al., 2016
atrioventricular valve shape, abnormal chemical treatment by environment: ethanol Fig. 4 with image from Sarmah et al., 2016
atrium position, abnormal chemical treatment by environment: ethanol Fig. 1 with image from Sarmah et al., 2017
basal communicating artery increased size, abnormal chemical treatment: LY-411575 Fig. 5 from Rochon et al., 2015
brain hemorrhagic, abnormal chemical treatment by environment: harmine Fig. 5. with image from Cho et al., 2019
cardiac ventricle decreased size, abnormal chemical treatment by environment: ethanol Fig. 1 with image from Sarmah et al., 2017
cardiac ventricle orientation atrium, abnormal chemical treatment by environment: ethanol Fig. 1 with image from Sarmah et al., 2017
cardiac ventricle orientation atrioventricular valve, abnormal chemical treatment by environment: ethanol Fig. 1 with image from Sarmah et al., 2017
cardiac ventricle position, abnormal chemical treatment by environment: ethanol Fig. 1 with image from Sarmah et al., 2017
central artery decreased amount, abnormal chemical treatment by environment: harmine Fig. 5. with image from Cho et al., 2019
central artery morphology, abnormal chemical treatment by environment: harmine Fig. 5. with image from Cho et al., 2019
cranial blood vessel artery morphogenesis process quality, abnormal chemical treatment: LY-411575 Fig. 5 from Rochon et al., 2015
cranial vasculature malformed, abnormal chemical treatment by environment: DAPT Fig 7 with image from Serrano et al., 2019
endocardial cell differentiation decreased process quality, abnormal chemical treatment: pharmaceutical Fig. 7 from Lagendijk et al., 2011
endocardium cell population proliferation decreased occurrence, abnormal chemical treatment by environment: DAPT Fig 7 with image from Serrano et al., 2019
endothelial tip cell cell population proliferation decreased rate, abnormal chemical treatment: aphidicolin, chemical treatment: hydroxyurea Fig. 7 with image from Nicoli et al., 2012
endothelial tip cell cell population proliferation decreased rate, normal chemical treatment: LY294002 Fig. 7 with image from Nicoli et al., 2012
head muscle ab-mf20 labeling spatial pattern, abnormal chemical treatment by environment: DAPT Fig 7 with image from Serrano et al., 2019
heart morphology, abnormal chemical treatment by environment: ethanol Fig. 1 with image from Sarmah et al., 2017
hyaluronan biosynthetic process increased occurrence, abnormal chemical treatment: pharmaceutical Fig. 7 from Lagendijk et al., 2011
intersegmental vessel decreased amount, abnormal chemical treatment by environment: doxorubicin, chemical treatment by environment: methoxypoly(ethylene glycol), chemical treatment by environment: poly(caprolactone) polymer, chemical treatment by environment: Honokiol Fig. 10 with image from Gao et al., 2017
intersegmental vessel decreased size, abnormal chemical treatment by injection: quercetin, chemical treatment by injection: poly(caprolactone) polymer, chemical treatment by injection: methoxypoly(ethylene glycol) Fig. 5 from Wu et al., 2013
intersegmental vessel incomplete structure, abnormal chemical treatment: borrelidin Fig. 5 with image from Mirando et al., 2015
intersegmental vessel truncated, abnormal chemical treatment: borrelidin Fig. 5 with image from Mirando et al., 2015
intersegmental vessel unlumenized, abnormal chemical treatment by environment: BAY-826 Fig. 7 from Francis et al., 2021
intersegmental vessel blood circulation decreased process quality, abnormal chemical treatment by environment: BAY-826 Fig. 7 from Francis et al., 2021
intersegmental vessel blood vessel lumenization decreased process quality, abnormal chemical treatment by environment: BAY-826 Fig. 7 from Francis et al., 2021
lateral dorsal aorta morphology, normal standard conditions Fig. 3 with image from Siekmann et al., 2009
pericardium edematous, abnormal chemical treatment by environment: DAPT Fig 7 with image from Serrano et al., 2019
primordial hindbrain channel morphology, normal standard conditions Fig. 3 with image from Siekmann et al., 2009
sternohyoid deformed, abnormal chemical treatment by environment: DAPT Fig 7 with image from Serrano et al., 2019
superior ocular sulcus blood vessel increased amount, abnormal chemical treatment by environment: Cyclopamine Fig. S7 with image from Hocking et al., 2018
superior ocular sulcus blood vessel mislocalised, abnormal chemical treatment by environment: Cyclopamine Fig. S7 with image from Hocking et al., 2018
superior ocular sulcus blood vessel morphology, abnormal chemical treatment by environment: Cyclopamine Fig. S7 with image from Hocking et al., 2018
trunk vasculature has normal numbers of parts of type intersegmental vessel, normal chemical treatment by environment: BAY-826 Fig. 7 from Francis et al., 2021
trunk vasculature morphology, normal chemical treatment by environment: prinomastat hydrochloride Fig. 2 with image from Theodore et al., 2017
trunk vasculature morphology, normal chemical treatment by environment: N(2)-([biphenyl]-4-ylsulfonyl)-N-hydroxy-N(2)-isopropoxy-D-valinamide Fig. 2 with image from Theodore et al., 2017
trunk vasculature morphology, normal chemical treatment by environment: MMP9 inhibitor I Fig. 2 with image from Theodore et al., 2017
trunk vasculature morphology, normal standard conditions Fig. 3 with image from Siekmann et al., 2009
ventral wall of dorsal aorta hematopoietic multipotent progenitor cell GFP expression spatial pattern, abnormal chemical treatment by environment: prinomastat hydrochloride Fig. 2 with image from Theodore et al., 2017

CITATIONS  (94)

Your Input Welcome
We welcome your input and comments. Please use this form to recommend updates to the information in ZFIN. We appreciate as much detail as possible and references as appropriate. We will review your comments promptly.
Please check the highlighted fields and try again.
Thank you for submitting comments. Your input has been emailed to ZFIN curators who may contact you if additional information is required.
Oops. Something went wrong. Please try again later.